SEC Tracker
Get the app
DTIL · XBRL financial data

Precision Biosciences financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (DTIL's year ends in late December)

In thousands of dollarsDec 31, 2023†Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026Sep 30, 2026
Revenue from contracts with customers7,038*17,58449,898576638*29181334,204*10,83800
Research and development13,389*13,34317,22513,08415,907*13,58812,76813,35214,464*13,11012,39412,745
General and administrative8,539*8,4288,5278,7679,577*8,5539,1277,3287,232*6,8036,7677,683
Total operating expenses21,928*21,77125,75221,85125,484*22,14121,89520,68021,696*19,91319,16120,428
Operating income (loss)(14,890)*(4,187)24,146(21,275)(24,846)*(22,112)(21,877)(20,667)12,508*(9,075)(19,161)(20,428)
Interest expense579*574560256392*354358362348*311300307
Other income (expense)1,456*12,7758,6034,8507,101*1,547(1,643)(1,105)6,740*(9,366)(13,491)12,842
Income tax expense (benefit)————year only———year only———
Net income (loss)(16,289)*8,58832,749(16,425)(17,745)*(20,565)(23,520)(21,772)20,133*(18,441)(32,652)(7,586)
Earnings per share, basic USD per share—1.704.70(2.25)—(2.21)(2.13)(1.84)—(0.75)(1.26)(0.28)
Earnings per share, diluted USD per share—1.704.67(2.25)—(2.21)(2.13)(1.84)—(0.75)(1.26)(0.28)
Weighted average shares, basic thousands of shares—5,0616,9677,2877,999*9,29211,04611,818—24,63425,85727,433
Weighted average shares, diluted thousands of shares—5,0637,0127,2878,155*9,29211,04611,818—24,63425,85727,433
  • † Share count changed about 30x in the period ending 2024-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Balance sheet

CSV

Fiscal quarters (DTIL's year ends in late December)

In thousands of dollarsDec 31, 2023†Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026Sep 30, 2026
Cash and cash equivalents116,678137,766123,57198,75285,89977,22362,24244,870110,82399,37086,07681,698
Marketable securities———2,450413—004,7621,8141,473148
Accounts receivable90139020718822940404,00000
Total current assets136,359160,828144,035110,52394,98982,10370,25951,705118,740108,69391,54986,575
Property and equipment, net6,3385,2864,2273,5633,0892,7172,3562,0261,4251,183964779
Right-of-use asset8,2637,9797,6897,3937,0906,7806,4626,1385,8055,4645,1144,756
Total assets159,781184,741165,800153,258136,388124,411108,92893,510154,416143,891125,920120,376
Accounts payable2,9681,1361,1449581,3129241,1211,340296944828813
Total current liabilities49,98733,33832,95711,98214,98012,39313,56814,9968,9137,7557,1408,270
Lease liability, non-current7,7237,4117,0916,7546,4046,0465,6805,2964,8974,4904,0723,636
Total liabilities140,920147,53591,08688,39279,99575,07474,87476,87662,16867,79080,62768,601
Accumulated deficit(489,631)(481,043)(448,294)(464,719)(482,464)(503,029)(526,549)(548,321)(528,188)(546,629)(579,281)(586,867)
Total stockholders' equity18,86137,20674,71464,86656,39349,33734,05416,63492,24876,10145,29351,775
Total liabilities and equity159,781184,741165,800153,258136,388124,411108,92893,510154,416143,891125,920120,376
Common shares outstanding (cover page)‡ thousands of shares2316,9267,2347,67110,48211,08811,78713,25724,72725,80227,60227,936
  • ‡ Per-share figures and share counts are adjusted for the 1-for-30 stock split (February 2024); filings made before it reported them unadjusted.
  • † Share count changed about 30x in the period ending 2024-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Cash flows

CSV

Fiscal quarters (DTIL's year ends in late December)

In thousands of dollarsDec 31, 2023†Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026Sep 30, 2026
Net income (loss)(16,289)*8,58832,749(16,425)(17,745)*(20,565)(23,520)(21,772)20,133*(18,441)(32,652)(7,586)
Stock-based compensation2,969*2,9062,928*3,199*3,571*2,8222,937*2,386*2,041*1,5491,844*2,958*
Net cash from operating activities(8,423)*(18,981)(14,869)*(5,912)*(18,683)*(19,052)(20,271)*(15,270)*(11,250)*(11,937)(13,442)*(15,132)*
Net cash from investing activities42*(26)(28)*(64)*(97)*(314)(12)*17*(325)*(114)1*(200)*
Proceeds from issuing common stock2,827*———————————
Net cash from financing activities2,828*40,095702*3,733*5,920*10,6875,300*1,659*77,516*7450*10,960*
Net change in cash(5,553)*21,088(14,195)*(2,243)*(12,860)*(8,679)(14,983)*(13,594)*65,941*(11,306)(13,441)*(4,372)*
  • † Share count changed about 30x in the period ending 2024-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Compare with peers

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Precision Biosciences81,6980(15,132)*27.9M6.1 quarters 10-QSep 30, 2026
Opus Genetics88,812755(11,950)*83.2M7.4 quarters 10-QJun 30, 2026
Acumen Pharmaceuticals53,075not reported(26,653)*72.3M3.4 quarters 10-QSep 30, 2026
Immucell8,8607,1863,019*9.1M— 10-QJun 30, 2026
Fortress Biotech196,57618,718(59,277)*33.3M3.3 quarters 10-QJun 30, 2026
Fitlife Brands1,089not reported3,635*9.4M— 10-QJun 30, 2026
Actinium Pharmaceuticals36,47335,000(5,179)*31.4M7.0 quarters 10-QJun 30, 2026
Lite Strategy5,706not reported(1,164)*30.4M4.9 quarters 10-KJun 30, 2026
Cue Biopharma17,3927,877(29,004)*7.3M0.6 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.